By Sandra Lora Cremers, MD, FACS
Board-Certified Ophthalmologist & Fellow, American College of Surgeons
Visionary Eye Doctors, Rockville, MD
Updated April 2026
It is the best time in history to have cataract surgery. If you are considering cataract surgery in 2026, you are choosing from the best lens technology that has ever existed. In the last 18 months, three game-changing lenses have either launched or received FDA approval — the Clareon PanOptix Pro, the TECNIS PureSee, and the enVista Envy which adds to the also excellent option of Light Adjustable Lenses— and I want to give you a comprehensive, evidence-based breakdown of every option available so you can have a truly informed conversation with your surgeon.
This updated chart now includes three separate vision columns: percent achieving 20/20 for distance, intermediate (computer/arm's length), and near (reading). I've also added extensive PubMed-verified footnotes so you (and your doctor) can look up the original data.
🔬 What's New in 2025–2026
1. Clareon PanOptix Pro (Alcon) — US Launch May 2025: if you are candidates for this lens (within healthy limits for macula, nerve, tear film —do not have a macular hole or significant glaucoma, nor significant dry eye disease/keratitis), my patients, love this lens, and so do I!
The original PanOptix has been the world's most-implanted trifocal IOL, with over 3 million lenses placed globally and a meta-analysis of 13 studies (513 bilateral patients) showing a pooled spectacle independence rate of 91.6% across all distances[12]. The Pro version keeps the same proven 40cm/60cm/∞ trifocal design but upgrades with ENLIGHTEN NXT technology: 94% light utilization (up from 88%) and 50% less light scatter[15]. Bench testing shows a 16% improvement in optical image contrast between distance and intermediate vision. Prospective trials are ongoing (NCT06400745; NCT06401551)[16]. Early clinical series (n=54 eyes) show 20/32 or better monocular from plano to −2.50D at one month[17]. For patients who want the most glasses-freedom at all distances, PanOptix Pro is now the top trifocal option.
2. TECNIS PureSee (J&J Vision) — FDA Approved March 12, 2026
This is the most significant EDOF approval in years. The PureSee is the first and only FDA-approved EDOF lens with no warning about loss of contrast sensitivity[10]. Unlike diffractive lenses, it uses a purely refractive posterior surface design — no rings, no light splitting. In the pivotal RCT (n=60 PureSee vs n=57 Eyhance), PureSee patients achieved a mean monocular CDVA of 20/15 for distance and mean DCIVA of 20/25 for intermediate, with a statistically significant 1.5-line improvement in intermediate vision over the TECNIS 1-Piece[9]. Critically, 97% of patients reported no very bothersome visual disturbances, and 97% would recommend the lens to friends and family[11]. Nearly 500,000 eyes have been implanted globally[10]. If you want extended range of vision but are worried about halos, or if you have mild eye disease that rules out a trifocal, PureSee will be a fantastic option when it becomes commercially available later this year.
3. enVista Envy (Bausch + Lomb) — FDA Approved October 2024
Bausch + Lomb's full-visual-range trifocal. In the randomized US clinical trial (n=332), 92% achieved 20/20 distance, 83% achieved 20/25+ intermediate, and patients reached J1 near acuity[21]. The Canadian trial (n=110) showed 93% moderate-to-complete satisfaction with near vision and 92% not needing spectacles for near tasks[22]. The ActivSync optic intelligently redistributes light based on pupil size — equalizing focal points in bright light but prioritizing distance in dim conditions. The enVista Envy also has the broadest toric range in any FVR IOL: cylinder powers from +0.90D to +5.75D at the IOL plane, with half-diopter steps up to +3.50D[24]. Note: a brief voluntary recall in early 2025 linked to a raw material vendor (TASS concern) has been fully resolved[23].
📊 Complete IOL Comparison Chart — April 2026
Scroll horizontally on mobile. Superscript numbers refer to the footnotes below.
| IOL Name | Category | % 20/20 Distance |
% 20/20 Intermediate |
% 20/20 Near/Reading |
Spectacle Independence |
Halos/Glare (Bothersome) |
Key Innovation | Refs |
|---|---|---|---|---|---|---|---|---|
| Standard Monofocal (SN60WF) |
Monofocal | ~90% | N/A (single focus) |
<5% | <5% | <1% | Insurance-covered baseline | [1] |
| enVista MX60 | Monofocal | ~90% | N/A (single focus) |
<5% | <5% | <1% | Glistening-free; aberration-neutral | [2] |
| TECNIS Eyhance (ICB00) |
Enhanced Monofocal |
~90–95% | ~50–60% (20/25 mean) |
~10% | 15–25% | <2% | Higher-order asphere; +1 line DCIVA vs mono | [3][4] |
| enVista Aspire (MX60E) |
Enhanced Monofocal |
~90–95% | ~50–60% (20/25 mean) |
~10% | 15–25% | <2% | Posterior aspheric +1.25D depth of focus | [5] |
| AcrySof IQ Vivity (DFT015) |
EDOF | ~94% (20/25+) |
97% ≥20/32 (mean ~20/25 binoc at 66cm) |
15–33% (20/32–20/40) |
33–53% | 1–7% | X-WAVE non-diffractive; monofocal-like halos | [6][7][8] |
| ⭐ TECNIS PureSee (ZEN00V) NEW — FDA Mar 2026 |
EDOF | ~95% (mean 20/15) |
~80–85% (mean DCIVA 20/25 at 66cm) |
Some (DCNVA ~20/40) |
60–70% | 3% (97% no bother) |
1st EDOF: NO contrast-loss warning; purely refractive | [9][10][11] |
| Clareon PanOptix (TFNT00) |
Trifocal | ~95%+ | ~90–95% (20/25 at 60cm) |
80–92% (20/25+ at 40cm) |
80–92% | ~5% | ENLIGHTEN; 40/60/∞; 3M+ implanted; 99% choose again | [12][13][14] |
| ⭐ Clareon PanOptix Pro (PXYWT0) NEW — US May 2025 |
Trifocal | ~95%+ | ~90–95% (20/25 at 60cm) |
80–92% | 80–92% | ~2.5–3% (50% less scatter) |
ENLIGHTEN NXT: 94% light util; +16% contrast | [15][16][17] |
| TECNIS Odyssey (DRN00V) |
FVR | ~93–95% | ~85–90% (continuous curve) |
75–85% | 85–93% | 3–5% | Continuous FVR defocus curve; broader than PanOptix | [18][19][20] |
| ⭐ enVista Envy (MX60EF) NEW — FDA Oct 2024 |
FVR Trifocal | 92% | 83% (20/25+ at ~60cm) |
~80% (J1 near) |
~90% | ~14% (86% minimal) |
ActivSync pupil-adaptive; broadest toric range | [21][22][23][24] |
| Light Adjustable Lens (LAL / LAL+, RxSight) |
Adjustable Monofocal |
70% (FDA) 95%+ (real-world) |
Depends on adjustment target † |
Depends on adjustment target † |
70–80% (w/ blended vision) |
<2% | Only IOL customizable after surgery; LASIK-like 92% within 0.5D | [25][26][27][28][29] |
† Important Note on the Light Adjustable Lens — Near & Intermediate Vision
The LAL is inherently a monofocal lens. Unlike trifocals or EDOFs, it does not have built-in focal points for intermediate or near. The uncorrected intermediate and near vision you achieve depends entirely on where your surgeon aims the focal point during the post-operative UV light adjustment:
- Both eyes plano (distance): Best 20/20 distance; readers needed for near and intermediate.
- Mini-monovision (dominant eye plano, non-dominant −0.50 to −1.00D): Functional intermediate ~20/25; near ~J2–J3; distance preserved ~20/20–20/25 binocularly.
- LAL+ model: Adds an anterior aspheric modification that enhances depth of focus before UV adjustment. Combined with mini-monovision, patients can achieve J1–J2 near and 20/25 intermediate.
- Unique advantage: The LAL is the only IOL that lets patients "test-drive" monovision before lock-in — if they dislike it, the surgeon can readjust toward emmetropia before the final UV lock-in treatment[25].
🧠My Take: How I Counsel Patients
Want maximum glasses-freedom at ALL distances? → PanOptix Pro, TECNIS Odyssey, or enVista Envy. These trifocal/FVR lenses give the best shot at ditching readers entirely. Trade-off: some chance of halos.
Worried about halos but still want extended range? → Vivity or the brand-new TECNIS PureSee. Non-diffractive EDOFs with great distance and intermediate and a near-monofocal dysphotopsia profile. You'll likely still need readers for fine print.
Had LASIK/PRK or have tricky corneas? → The Light Adjustable Lens gives you LASIK-like precision with post-op customization. 92% within 0.5D of target[25]. You can even test-drive monovision before committing.
Have glaucoma, mild macular disease, or want the simplest option? → A standard monofocal or enhanced monofocal (Eyhance or Aspire) is still excellent and insurance-covered.
📎 Download the Full Spreadsheet
The detailed Excel file includes additional columns for contrast sensitivity, light utilization %, toric availability, explant rates, and a full Footnotes & PubMed References sheet.
Download IOL Comparison Chart 2026 v2 (Excel)
📚 Footnotes & PubMed-Verified References
[1] Standard monofocal IOLs: insurance-covered baseline. Readers always required for near/intermediate.
[2] Heiner P et al. Safety and effectiveness of a single-piece hydrophobic acrylic IOL (enVista). Clin Ophthalmol. 2014;8:629-635. PMID: 24741291.
[3] Mencucci R et al. Visual outcomes with a new enhanced monofocal IOL (TECNIS Eyhance ICB00). J Cataract Refract Surg. 2020;46(10):1328-1333. PMID: 33259391.
[4] Eyhance provides ~1 extra line of DCIVA vs standard monofocal; no dysphotopsia warning. TECNIS Eyhance DFU.
[5] enVista Aspire (MX60E): posterior high-order aspheric surface, +1.25D depth of focus. Bausch+Lomb DFU.
[6] Shafer BM et al. The REVIVE Study: Long-term outcomes of a novel non-diffractive extended vision IOL vs monofocal. Clin Ophthalmol. 2022;16:3997-4004. PMID: 36510491.
[7] Hovanesian JA, Jones M, Allen Q. The Vivity EDOF vs PanOptix, ReStor 2.5 & 3.0: comparison of satisfaction, disturbances, spectacle independence. Clin Ophthalmol. 2022;16:145-152. PMID: 35082481.
[8] Vivity FDA trial (n=107): 98%/97%/58% reached ≥20/32 binoc dist/intermed/near. Vivity Registry (n=885, 8 countries): 91% no halos. FDA PMA P930014/S126.
[9] Liang E et al. Quality of vision outcomes for a new fully-refractive extended depth of focus IOL. Eye Vis. 2024;11:16. PMID: 38735975 (PMC 11080637).
[10] TECNIS PureSee FDA approval March 12, 2026. ~500K eyes globally. 1.5-line mean monocular DCIVA gain vs TECNIS 1-Piece. J&J Vision press release.
[11] 97% no very bothersome visual disturbances; 97% recommend to friends/family. DFU Model DEN00V, Rev B.
[12] Zhu D, Ren S, Mills K, et al. Rate of complete spectacle independence with a trifocal IOL: systematic review and meta-analysis. Ophthalmol Ther. 2023;12(2):1157-1171. PMID: 36698016.
[13] Kohnen T, Lapid-Gortzak R, Ramamurthy D, et al. Clinical outcomes after bilateral implantation of a diffractive trifocal IOL: worldwide pooled analysis. Clin Ophthalmol. 2023;17:155-163. PMID: 36660551.
[14] PanOptix FDA PMA P040020/S087. 99.2% would choose same lens. 4.8% very much bothered by starbursts.
[15] Alcon PanOptix Pro DFU (PXYWT0). ENLIGHTEN NXT: 94% light utilization, 50% less scatter, +16% contrast improvement.
[16] ClinicalTrials.gov NCT06400745; NCT06401551 (ongoing PanOptix Pro prospective trials).
[17] Early series (n=54 eyes/27 pts): 20/32+ monocular from plano to −2.50D at 1 month. ASCRS/trade-journal preliminary data; peer-reviewed confirmation pending.
[18] TECNIS Odyssey (DRN00V): FDA PMA supplement approval 2024. Full Visual Range IOL. J&J launch announcement.
[19] ClinicalTrials.gov NCT05991960 (Odyssey real-world registry).
[20] J&J data: 14% smaller readable print vs PanOptix; ~93% spectacle-free. Manufacturer-reported; independent confirmation needed.
[21] Shultz MC, Wiley WF, Liang E, et al. Visual and patient-reported outcomes of a novel full visual range IOL vs monofocal: randomized multicenter US trial. Am J Ophthalmol. 2025. n=332.
[22] Muzychuk A, Harasymowycz H. Efficacy and safety of a new FVR vs monofocal IOL: randomized, controlled Canadian trial. JCRS. 2025. DOI:10.1097/j.jcrs.0000000000001714.
[23] Bausch+Lomb voluntary enVista TASS recall March 2025 (raw material vendor). Resolved; re-released with enhanced QC.
[24] enVista Envy Toric DFU: +0.90D to +5.75D IOL plane; half-diopter steps to +3.50D.
[25] FDA PMA P160055: LAL Phase 3 (n=600). 70.1% vs 36.3% 20/20 UCVA (p<.0001). 92% within 0.50D MRSE.
[26] Villegas EA, Alcon E, Artal P. Minimum amount of astigmatism that should be corrected. J Cataract Refract Surg. 2014;40(1):13-19. PMID: 24269139.
[27] Hengerer FH et al. Second-generation light-adjustable IOL: results. J Refract Surg. 2020;36(2):82-89. PMID: 32016425. 98% within ±0.50D.
[28] Ford JR et al. Clinical outcomes of LAL in eyes with prior corneal refractive surgery. J Cataract Refract Surg. 2024;50(9):937-941. PMID: 38861488. 74% 20/20; 88% 20/25.
[29] Leung EH et al. Visual outcomes of an enhanced UV-protected LAL using co-managed methodology. Clin Ophthalmol. 2022;16:2469-2476. PMID: 35937629. 97.2% emmetropic-goal eyes saw 20/20.
Disclaimer: Percentages are approximate and derived from published FDA trial data, Directions for Use, and peer-reviewed literature. Individual results vary based on ocular health, biometry, surgeon technique, and ocular surface optimization. This post is for educational purposes and does not constitute medical advice. Please discuss your options with your cataract surgeon.
Listen to more on The Eye Show podcast — I'll be doing a deep-dive episode on these new 2025–2026 lenses soon.
Sandra Lora Cremers, MD, FACS
Visionary Eye Doctors | 11300 Rockville Pike, Suite 1202, Rockville, MD 20852
Amazon Storefront · EyeDoc2020 Blog
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.